Rapamycin (Sirolimus) and Estradiol HRT Interaction: What Patients and Clinicians Need to Know

How Sirolimus and Estradiol Interact at the Molecular Level

Sirolimus (brand name Rapamune) is metabolized almost entirely by hepatic and intestinal CYP3A4, with P-glycoprotein (P-gp) controlling its absorption at the gut wall. Estradiol, particularly when taken orally, is also a CYP3A4 substrate and a weak inhibitor of the same enzyme. That shared pathway is the core of this interaction.

CYP3A4 Competition and Sirolimus Blood Levels

When two CYP3A4 substrates compete for the same enzyme, the one with higher affinity or concentration can slow the other's clearance. Oral estradiol undergoes extensive first-pass metabolism through CYP3A4 in the gut and liver, producing a local inhibitory effect that can meaningfully reduce sirolimus metabolism. The FDA label for Rapamune (sirolimus) explicitly identifies CYP3A4 inhibitors as agents requiring dose adjustment and trough monitoring, and oral contraceptives containing ethinyl estradiol are listed as clinically relevant CYP3A4 interactors in the label's drug-interaction section (FDA Rapamune Prescribing Information).

Ethinyl estradiol, the synthetic estrogen in oral contraceptives, is a stronger CYP3A4 inhibitor than the 17-beta estradiol used in HRT. Even so, a single-dose pharmacokinetic study by Zimmermann et al. Showed that co-administration of oral contraceptives containing ethinyl estradiol increased sirolimus mean AUC by approximately 11 to 13% and Cmax by roughly 14%, with the interaction driven primarily by gut-wall CYP3A4 inhibition (PubMed: Zimmermann et al.). Bioidentical 17-beta estradiol at HRT doses produces a smaller inhibitory signal, but the direction of effect is the same.

P-Glycoprotein and Absorption

P-gp acts as an efflux pump in the intestinal epithelium, ejecting sirolimus back into the gut lumen and limiting its absorption. Estradiol has weak P-gp substrate and modulator activity. The net P-gp contribution to this specific interaction is likely small compared with CYP3A4, but it adds to the unpredictability of sirolimus trough levels when estradiol formulations are changed.

Transdermal Route: Why It Matters

Transdermal estradiol (patches, gels, sprays) bypasses first-pass hepatic and intestinal metabolism almost entirely. Systemic estradiol levels achieved transdermally are clinically effective while producing negligible CYP3A4 inhibition in the gut wall. For that reason, the pharmacokinetic interaction with sirolimus is substantially smaller with transdermal delivery. Patients already stable on transdermal estradiol who are initiating sirolimus still need a baseline trough check, but the dose-adjustment probability is lower than with oral estradiol.

Pharmacodynamic Interaction: Overlapping VTE Risk

The pharmacokinetic interaction is only one dimension of this combination. Both sirolimus and estrogen-containing HRT independently raise the risk of venous thromboembolism (VTE), and their effects may be additive.

Estradiol HRT and VTE

Oral estrogen-containing HRT raises VTE risk approximately 2 to 3-fold compared with non-use. The Women's Health Initiative (WHI) randomized trial (N=16,608) reported a hazard ratio of 2.06 (95% CI 1.57 to 2.70) for VTE in women receiving conjugated equine estrogen plus medroxyprogesterone acetate versus placebo (PubMed: Cushman et al., WHI). Transdermal estradiol carries a substantially lower VTE risk than oral estradiol, a finding confirmed in the ESTHER study, a case-control analysis that found no statistically significant VTE elevation with transdermal estrogen (OR 0.9, 95% CI 0.45 to 1.8) compared with an OR of 3.5 (95% CI 1.8 to 6.8) for oral estrogen (PubMed: Canonico et al., ESTHER).

Sirolimus and VTE

Sirolimus itself carries a labeled VTE risk. Post-marketing data and case series have linked mTOR inhibitors to both arterial and venous thrombotic events, possibly through effects on platelet aggregation and endothelial function. The Rapamune prescribing information warns that sirolimus has been associated with increased thrombotic microangiopathy in certain populations, and a retrospective cohort analysis published in the American Journal of Transplantation found a 1.8-fold increase in VTE events in renal transplant recipients receiving sirolimus-containing regimens versus calcineurin inhibitor-based regimens (PubMed: Bren et al.).

Combined Risk Assessment

The North American Menopause Society (NAMS) 2022 Hormone Therapy Position Statement states: "Venous thromboembolism risk is higher with oral than transdermal estrogen-containing therapies, and risk is further modified by progestogen type and individual patient thrombophilic risk factors" (menopause.org). Adding sirolimus to that risk profile shifts the calculus. Patients with existing thrombophilic conditions (Factor V Leiden, prothrombin gene mutation, antiphospholipid antibodies) should be considered for additional risk stratification before combining these agents.

mTOR Inhibition and Estrogen-Driven Cell Biology

Sirolimus inhibits mTOR complex 1 (mTORC1), a serine-threonine kinase that sits at the intersection of nutrient sensing, cell proliferation, and hormone signaling. Estrogen drives cell proliferation partly through PI3K/Akt/mTOR pathway activation in breast and uterine tissue. This creates a biologically plausible pharmacodynamic interaction that is clinically distinct from the VTE question.

Breast Tissue: Potential Attenuation of Estrogen Signaling

Everolimus, a close structural analog of sirolimus, combined with exemestane demonstrated a 7.4-month improvement in progression-free survival in the BOLERO-2 trial (N=724) in postmenopausal women with hormone receptor-positive breast cancer, confirming that mTOR inhibition attenuates estrogen-driven proliferation (PubMed: Baselga et al., BOLERO-2). Whether longevity-dose sirolimus (typically 1 to 4 mg once weekly or 0.5 to 1 mg daily) produces clinically meaningful mTOR suppression in breast tissue of HRT users is unknown. Extrapolating oncologic trial data to low-dose longevity use requires caution.

Uterine Tissue and Endometrial Implications

Endometrial hyperplasia driven by unopposed estrogen involves the same PI3K/mTOR axis that sirolimus inhibits. No clinical trial has examined whether low-dose sirolimus modifies endometrial proliferation in HRT users. Women on estrogen-only HRT (typically post-hysterectomy) or combined estrogen-progestogen HRT should continue standard endometrial monitoring per current gynecologic guidelines regardless of sirolimus use.

Clinical Monitoring Protocol

Managing this combination requires a structured approach. The following protocol is extrapolated from the FDA Rapamune label, CYP3A4 interaction pharmacokinetics, and VTE risk data from the WHI and ESTHER studies.

Sirolimus Trough Monitoring

• Obtain a baseline whole-blood sirolimus trough (12-hour post-dose) before starting estradiol HRT or before switching estradiol formulations.
• Recheck the trough 10 to 14 days after initiating oral estradiol or after switching from transdermal to oral.
• Target trough range: 4 to 12 ng/mL for transplant indications per FDA labeling; off-label longevity targets typically 1 to 6 ng/mL per prescribing clinician protocol.
• If trough rises above the target range after adding oral estradiol, reduce the sirolimus dose by 10 to 25% and recheck in 10 to 14 days.
• Switching from oral to transdermal estradiol may lower sirolimus exposure; recheck trough 10 to 14 days after the switch to confirm levels remain therapeutic.

VTE Risk Stratification

• Obtain a personal and family history of VTE, thrombophilia testing if clinically indicated, and baseline D-dimer if the patient has risk factors.
• Prefer transdermal over oral estradiol in any patient on sirolimus, all else being equal, given the lower VTE signal and lower PK interaction.
• Counsel patients to report calf pain, leg swelling, dyspnea, or chest pain immediately.
• Review concurrent medications that raise VTE risk (progestogens with androgenic activity, antifibrinolytics, immobility risk).

Laboratory Baseline Panel

Before combining sirolimus with estradiol HRT, the following labs are recommended:

• Complete metabolic panel (CMP) including hepatic function (sirolimus is hepatically cleared)
• Fasting lipid panel (sirolimus raises triglycerides and total cholesterol in up to 40 to 50% of transplant patients per the Rapamune label)
• CBC with differential (sirolimus causes thrombocytopenia and anemia in a minority of patients)
• Whole-blood sirolimus trough
• Baseline coagulation screen if VTE risk factors are present

Dose Adjustment Guidance

No prospective dose-adjustment trial exists specifically for sirolimus plus 17-beta estradiol HRT. Guidance is extrapolated from the FDA label interaction section, ethinyl estradiol pharmacokinetic data, and CYP3A4 inhibitor classification frameworks.

Oral Estradiol Scenarios

Oral estradiol at standard HRT doses (0.5 to 2 mg/day 17-beta estradiol) produces moderate CYP3A4 inhibition at the gut wall. A reasonable starting assumption, based on the Zimmermann ethinyl estradiol/sirolimus PK study and the weaker inhibitory potency of 17-beta estradiol, is a 10 to 15% increase in sirolimus AUC. Patients on transplant-range sirolimus doses (typically 2 to 5 mg/day) may need a dose reduction of approximately 0.5 to 1 mg/day, confirmed by trough measurement. Patients on longevity-dose sirolimus (0.5 to 2 mg/day or 2 to 6 mg once weekly) face smaller absolute changes but the same relative PK shift; trough monitoring remains the most reliable guide.

Transdermal Estradiol Scenarios

Transdermal 17-beta estradiol at standard HRT doses (0.025 to 0.1 mg/24h patch; 0.5 to 1.5 g/day gel) bypasses intestinal CYP3A4 almost entirely. The expected effect on sirolimus trough is clinically negligible for most patients. A confirmatory trough check 10 to 14 days after initiation is still prudent, but empiric dose adjustment is rarely necessary.

Switching Between Formulations

When a patient transitions from transdermal to oral estradiol, sirolimus trough levels may rise within 1 to 2 weeks as gut-wall CYP3A4 inhibition increases. The reverse is also true: switching from oral to transdermal may lower sirolimus exposure and risk sub-therapeutic troughs in transplant patients. Each formulation change should trigger a trough recheck.

Patient Counseling Points

Patients combining sirolimus with estradiol HRT need specific, concrete information. Vague reassurance is not adequate for a combination with real pharmacokinetic and thrombotic implications.

Key Messages for Patients

1. Tell every prescribing clinician about both medications. Sirolimus is still unfamiliar to many gynecologists and primary care providers.
2. Do not switch estradiol formulations (pill to patch, patch to pill, brand to generic) without notifying the prescribing clinician first, because the switch can change sirolimus blood levels within two weeks.
3. Transdermal estradiol is generally preferred over oral when sirolimus is co-prescribed, for both pharmacokinetic and VTE reasons.
4. Blood clot warning signs (sudden leg swelling, warmth, redness; unexplained shortness of breath; chest pain) require same-day emergency evaluation.
5. Routine sirolimus blood level checks are not optional. Missing a trough draw after a medication change can result in either toxicity (high trough) or loss of therapeutic effect (low trough).
6. Sirolimus can raise cholesterol and triglycerides. Estradiol HRT can modestly raise triglycerides when taken orally. Lipid monitoring after combining the agents is warranted.

Special Populations

Post-menopausal women on longevity-dose sirolimus: This is the most common clinical scenario in off-label longevity programs. Sirolimus doses are lower, trough targets are less strict, and absolute PK interaction magnitude is smaller. Transdermal estradiol is a reasonable first choice if HRT is indicated.

Transplant recipients on therapeutic sirolimus: These patients have narrow therapeutic windows. A 10 to 15% trough increase from oral estradiol can push levels into the toxic range. Close coordination between transplant nephrology and gynecology is essential.

Women with hormone receptor-positive breast cancer history: mTOR inhibitors are active agents in hormone receptor-positive breast cancer (BOLERO-2 data). Resuming HRT after breast cancer treatment in a patient also taking sirolimus should involve oncology review.

What the FDA Label Says

The FDA Rapamune prescribing information (most recent revision 2021) classifies sirolimus as a CYP3A4 and P-gp substrate and explicitly states: "Avoid the use of strong CYP3A4 inhibitors (e.g., ketoconazole, voriconazole, itraconazole, telithromycin, or clarithromycin) and strong inducers of CYP3A4 (e.g., rifampin, rifabutin) with sirolimus" (FDA Rapamune label). Oral contraceptives are listed as moderate interactors requiring monitoring. 17-beta estradiol HRT at standard doses falls in the weak-to-moderate inhibitor category for CYP3A4, placing it below the threshold for a contraindication but above the threshold for indifference.

The FDA label also advises that sirolimus whole-blood trough concentrations should be monitored whenever CYP3A4 modulators are added, discontinued, or dose-changed. That instruction applies directly to estradiol formulation switches.

Interactions With Progestogens Used in HRT

Most women on systemic HRT who have an intact uterus use combined estrogen-progestogen therapy. The progestogen component adds another layer to the interaction picture.

Progesterone (Oral Micronized)

Oral micronized progesterone (Prometrium, Utrogestan) is a CYP3A4 substrate. Co-administration with sirolimus may produce bidirectional trough variability. A pharmacokinetic study by Picard et al. Found that oral micronized progesterone undergoes significant first-pass CYP3A4 metabolism, making it vulnerable to inhibition or competition from sirolimus (PubMed: Picard et al.). The clinical significance at HRT doses is likely modest, but it adds unpredictability.

Synthetic Progestogens

Medroxyprogesterone acetate (MPA) and norethindrone are also CYP3A4 substrates. The WHI trial used conjugated equine estrogen plus MPA, and it is this combination that carries the higher VTE signal (HR 2.06 in Cushman et al.). Women on sirolimus should discuss whether a progestogen with lower androgenic activity and lower VTE signal (such as micronized progesterone or dydrogesterone) is preferable. The ESTHER study showed micronized progesterone was associated with a lower VTE OR (0.7, 95% CI 0.3 to 1.9) compared with synthetic progestogens (PubMed: Canonico et al., ESTHER).